Abstract: An object of the present invention is to provide novel dextrin fatty acid ester that is excellent in tackiness and useful as a base for cosmetics and the like. The novel dextrin fatty acid ester is prepared by esterification between dextrin and fatty acids, wherein the dextrin has an average degree of glucose polymerization of 3 to 150; the fatty acids comprise more than 50 mol % and 100 mol % or less, based on the total amount of the fatty acids, of one or more saturated branched fatty acids having 4 to 26 carbon atoms, and 0 mol % or more and less than 50 mol %, based on the total amount of the fatty acids, of one or more fatty acids selected from the group consisting of saturated linear fatty acids having 2 to 22 carbon atoms, unsaturated linear or branched fatty acids having 6 to 30 carbon atoms, and saturated or unsaturated cyclic fatty acids having 6 to 30 carbon atoms; and the degree of substitution by the fatty acids is 1.0 to 3.0 per glucose unit.

Abstract: An object of the present invention is to provide novel dextrin fatty acid ester that is excellent in tackiness and useful as a base for cosmetics and the like. The novel dextrin fatty acid ester is prepared by esterification between dextrin and fatty acids, wherein the dextrin has an average degree of glucose polymerization of 3 to 150; the fatty acids comprise more than 50 mol % and 100 mol % or less, based on the total amount of the fatty acids, of one or more saturated branched fatty acids having 4 to 26 carbon atoms, and 0 mol % or more and less than 50 mol %, based on the total amount of the fatty acids, of one or more fatty acids selected from the group consisting of saturated linear fatty acids having 2 to 22 carbon atoms, unsaturated linear or branched fatty acids having 6 to 30 carbon atoms, and saturated or unsaturated cyclic fatty acids having 6 to 30 carbon atoms; and the degree of substitution by the fatty acids is 1.0 to 3.0 per glucose unit.

Abstract: A modified organopolysiloxane in which a carboxyl group of a heterocyclic compound having a carboxyl group and containing a nitrogen atom as a heteroatom is combined with an amino group of an amino-modified silicone is used as a gelling agent for low-viscosity silicone oil, which can allow the low-viscosity silicone oil to stably gel without losing the characteristics thereof.

Abstract: A pure culture of Pantoea agglomerans having all of the characteristics of FERM BP-3511 is disclosed. The characteristics include morphology, growth, physiological, carbon utilization sources and various enzymatic tests, as well as the required production of a lipopolysaccharide and all of these characteristics have been identified for the culture of P. agglomerans. In addition the lipopolysaccharide has a dominant molecular weight of 6,500.+-.2,500 as determined by SDS-PAGE method, 2.+-.phosphorus, 5.+-.hexosamines and 2.+-.1 2-keto-3-deoxyoctonate per molecular weight of 5,000. The specific enzymatic tests involve such enzymes as lysin decarboxylase, arginine dihydroxylase, phenylalanine deaminase and ornithine decarboxylase. Further, a test for utilization of malonate by the culture is disclosed.

Abstract: Antiwithdrawal agents and veterinary antiwithdrawal agents are disclosed which contain lipopolysaccharide (LPS) representatives which have the following physical properties:LPS1 Dominant molecular weight: 5,000.+-.1,000 as determined by SDS-PAGR method______________________________________ Phosphorus number: 2 .+-. 1/5,000 (m.w.) Hexosamine number: 9 .+-. 1/5,000 (m.w.) KDO number: 2 .+-. 1/5,000 (m.w.); ______________________________________LPS2 Dominant molecular weight: 6,500.+-.2,500 as determined by SDS-PAGR method ______________________________________ Phosphorus number: 1 to 2/5,000 (m.w.) Hexosamine number: 7 .+-. 1/5,000 (m.w.) KDO number: 1 to 2/5,000 (m.w.); and ______________________________________LPS3 Dominant molecular weight:6,500.+-.2,500 as determined by SDS-PAGE method ______________________________________ Phosphorus number: 2 .+-. 1/5,000 (m.w.) Hexosamine number: 5 .+-. 1/5,000 (m.w.) KDO number: 2 .+-. 1/5,000 (m.w.

Abstract: A limulus test-positive plant glycolipid having the following properties: molecular weight: 8000 .+-.1000 by SDS electrophoresis, number of phosphorous not less than 1/mol; number of hexosamine 6 .+-.2/mol; number of fatty acids 6 .+-.2/mol is effective in the stimulation of osteogenesis, oviposition and shell strength improvement in animals. The glycolipid may be administered as a composition comprising an effective amount of the glycolipid in admixture with a pharmaceutically or veterinarily acceptable carrier, such that when administered to an animal, the immune system of the animal is favorably stimulated.

Abstract: Novel LPS having the following physical properties, novel bacilli providing those LPS, and novel immunity stimulators, anagesics, and antiwithdrawal agents, and novel veterinary immunity stimulators, analgesics, and antiwithdrawal agents containing LPS selected from the group consisting of those LPSs and mixtures thereof.LPS1 Dominant molecular weight: 5,000.+-.1,000 as determined by______________________________________ SDS-PAGE method ______________________________________ Phosphorus number: 2 .+-. 1/5,000 (m.w.) Hexosamine number: 9 .+-. 1/5,000 (m.w.) KDO number: 2 .+-. 1/5,000 (m.w.) ______________________________________LPS2 Dominant molecular weight: 6,500.+-.2,500 as determined by ______________________________________ SDS-PAGE method ______________________________________ Phosphorus number: 1 to 2/5,000 (m.w.) Hexosamine number: 7 .+-. 1/5,000 (m.w.) KDO number: 1 to 2/5,000 (m.w.) ______________________________________ LPS3 Dominant molecular weight: 6,500.+-.

Abstract: An analgesic composition comprising an effective amount of at least one member of LPS whose macrophage activation ED.sub.50 is 0.

Abstract: A limulus test-positive plant glycolipid having the following properties:molecular weight: 8000.+-.1000 (SDS electrophoresis)number of phosphorus: not less than 1/mol.number of hexosamine: 6.+-.2/mol.number of fatty acid: 6.+-.2/mol is effective in the stimulation of osteogenesis, oviposition and shell strength improvement in animals. The glycolipid may be administered as a composition comprising an effective amount of said glycolipid in admixture with a pharmaceutically or veterinarily acceptable carrier, such that when administered to an animal, the immune system of said animal is favorably stimulated.